DA Davidson analyst Gil Luria lowered the firm’s price target on Teladoc to $18 from $22 and keeps a Neutral rating on the shares. The company’s Q4 results missed expectations on several key metrics across both Integrated Care and BetterHelp, while its three-year outlook is suggestive of mid-single-digit annual revenue growth at best, the analyst tells investors in a research note. The firm adds however that Teladoc’s margin accretion has been solid and should continue as Teladoc implements what appears to be a strong cost-to-benefit proposition.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TDOC:
- Teladoc Inc. Earnings Update: Did it Beat Estimate Forecasts?
- Teladoc (NYSE:TDOC) Delivers Mixed Q4, Stock Drops On Downbeat Outlook
- Teladoc Health Reports Fourth Quarter and Full Year 2023 Results
- Options Volatility and Implied Earnings Moves Today, February 20, 2024
- Teladoc Health Provides Updated Start Time for Fourth Quarter 2023 Earnings Call on February 20, 2024